QIAGEN Singapore Pte. Ltd. has partnered with Parkway Laboratories, one of Singapore's leading clinical laboratories, to advance healthcare services through the installation of the QIAstat-Dx syndromic testing system in three of IHH Healthcare's hospitals in Singapore's Gleneagles, Mount Elizabeth and Mount Elizabeth Novena hospitals.

The collaboration aims to enhance patient management by optimizing syndromic testing diagnosis and treatment with accurate pathogen identification. By connecting to the QIAsphere, QIAstat-Dx provides Parkway Laboratories with valuable epidemiological trends to support public healthcare management.

QIAstat-Dx, a multiplex molecular diagnostic system, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens, with results in about an hour, thereby providing rapid answers for the detection of a wide range of infections.

The disease area panels include the QIAstat-Dx Respiratory SARS-CoV-2 Panel, QIAstat-Dx Gastrointestinal Panel, and QIAstat-Dx Meningitis/Encephalitis Panel. The QIAstat-Dx system also provides easy-to-view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques.

William Lin, Senior Director, Commercial Operation, APEC at QIAGEN said "By providing fast and accurate syndromic testing solutions across respiratory, gastrointestinal, and central nervous system infections, we're enabling healthcare providers to make informed decisions quickly, potentially reducing unnecessary antibiotic use and supporting antimicrobial stewardship efforts."